Frequent intravenous pulses of growth hormone together with alanylglutamine supplementation in prolonged critical illness after multiple trauma: Effects on glucose control, plasma IGF-I and glutamine

被引:16
作者
Duska, Frantisek [1 ,2 ]
Fric, Michal [1 ]
Pazout, Jaroslav [1 ]
Waldauf, Petr [1 ]
Tuma, Petr [2 ]
Pachl, Jan [1 ]
机构
[1] Charles Univ Prague, Fac Med 3, Dept Anaesthesia & Crit Care Med, Prague 10034, Czech Republic
[2] Charles Univ Prague, Fac Med 3, Dept Biomed Sci, Prague 11000, Czech Republic
关键词
prolonged critical illness; multiple trauma; glutamine; growth hormone; IGF-I; glucose control;
D O I
10.1016/j.ghir.2007.07.003
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objective: We aim to demonstrate that low dose growth hormone (GH) administered in i.v. pulses every 3 It is able to normalize IGF-I levels in subjects with prolonged critical illness, after multiple trauma. We also ask whether it is possible to control glycaemia during such a treatment and how alanylglutamine (AG) supplementation influences plasma glutamine concentration. Methods: We used a prospective double-blind (group I vs. 2), randomized trial with an open-label control arm (group 3). Thirty multiple trauma patients (median age: 36, 42, 46 years) were randomized on day 4 after trauma to receive (group 1, n = 10) i.v. AG supplementation (0.3 g/kg day from day 4 till 17) and i.v. GH (0.05 mg/kg day divided into 8 boluses, maximum dose at 3 AM, administered on days 7-17) or AG and placebo (group 2, n = 10). Group 3 (n = 10) received isocaloric isonitrogenous (proteins 1.5 g/kg day) nutrition without AG. Glycaemia was controlled by i.v. insulin infusion according to a routine protocol. Results: GH treatment caused an increase of IGF-I (from median 169 on day 4 to 493 ng/ml on day 17), IGFBP-3 (from 2.4 to 3.2 mu g/ml) and a fall in IGFBP-1 (from 11.5 to 3.1 mu g/ml), whilst in both groups 2 and 3 these indices remained unchanged. At the end of the study (day 17) IGF-I and IGFBP-1 differed significantly among groups (p = 0.008 resp. p = 0.010, Kruskal-Wallis). Plasma glutamine remained below the normal range through the study in all groups (median: 0.18-0.30 mM), but had a tendency to rise in group 2 in contrast with a fall in groups I and 3 (NS). Group I required more insulin (p < 0.01) than did the control group but median glycaemia was only 0.4-0.5 mM higher in group 1 (6.5 mM) than in groups 2 and 3 (6.1 resp. 6.0 mM). Conclusions: GH (0.05 g/kg day) administered in i.v. pulses is able to normalize IGF-I levels in subjects with prolonged critical illness after trauma. During this treatment, the standard dose of AG prevents worsening of plasma glutamine deficiency and glucose control is possible using routine algorithms, but it requires higher insulin doses. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:82 / 87
页数:6
相关论文
共 26 条
[1]  
ANDREWS FJ, 2002, BR J NUTR S1, V1, pS3
[2]   Parenterally administered dipeptide alanyl-glutamine prevents worsening of insulin sensitivity in multiple-trauma patients [J].
Bakalar, B ;
Duska, F ;
Pachl, J ;
Fric, M ;
Otahal, M ;
Pazout, J ;
Andel, M .
CRITICAL CARE MEDICINE, 2006, 34 (02) :381-386
[3]   INJURY SEVERITY SCORE - METHOD FOR DESCRIBING PATIENTS WITH MULTIPLE INJURIES AND EVALUATING EMERGENCY CARE [J].
BAKER, SP ;
ONEILL, B ;
HADDON, W ;
LONG, WB .
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 1974, 14 (03) :187-196
[4]   Rethink about growth-hormone therapy for critically ill patients [J].
Bengtsson, BÅ .
LANCET, 1999, 354 (9188) :1403-1404
[5]   Growth hormone decreases muscle glutamine production and stimulates protein synthesis in hypercatabolic patients [J].
Biolo, G ;
Iscra, F ;
Bosutti, A ;
Toigo, G ;
Ciocchi, B ;
Geatti, O ;
Gullo, A ;
Guarnieri, G .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2000, 279 (02) :E323-E332
[6]  
BRISMAR K, 2004, J CLIN ENDOCR METAB, V79, P872
[7]   The role of glutamine in intensive care unit patients:: Mechanisms of action and clinical outcome [J].
Coëffier, M ;
Déchelotte, P .
NUTRITION REVIEWS, 2005, 63 (02) :65-69
[8]  
COUFAL P, 2001, ELECTROANAL, V13, P989
[9]   THE OPTIMAL-GROWTH HORMONE REPLACEMENT DOSE ADULTS, DERIVED FROM BIOIMPEDANCE ANALYSIS [J].
DEBOER, H ;
BLOK, GJ ;
VOERMAN, B ;
DEVRIES, P ;
POPPSNIJDERS, C ;
VANDERVEEN, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (07) :2069-2076
[10]   Growth hormone therapy in critically ill patients [J].
Demling, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (11) :837-839